Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The revenue for TriSalus Life Sciences, Inc. - Equity Warrant as of June 30, 2025 is 35.99 MM.
- The operating income for TriSalus Life Sciences, Inc. - Equity Warrant as of June 30, 2025 is -30.98 MM.
- The net income for TriSalus Life Sciences, Inc. - Equity Warrant as of June 30, 2025 is -31.17 MM.
| Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
| 2025-06-30 | 35.99 | -30.98 | -31.17 |
| 2025-03-31 | 32.14 | -31.82 | -27.21 |
| 2024-12-31 | 29.43 | -36.16 | -30.05 |
| 2024-09-30 | 26.89 | -41.12 | -55.58 |
| 2024-06-30 | 24.74 | -48.47 | -54.66 |
| 2024-03-31 | 21.98 | -51.73 | -64.30 |
| 2023-12-31 | 18.51 | -50.17 | -59.36 |
| 2023-09-30 | 16.02 | -47.67 | -46.27 |
| 2023-06-30 | 14.75 | -41.44 | -52.88 |
| 2023-03-31 | 13.01 | -38.67 | -47.58 |
| 2022-12-31 | 12.40 | -36.44 | -47.19 |
| 2022-09-30 | 11.74 | -31.00 | -31.61 |
| 2021-12-31 | 8.40 | -24.03 | -28.84 |
| 2020-12-31 | 5.43 | -25.65 | -31.83 |
Income Statement: EPS
| Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
| 2025-06-30 | ||
| 2025-03-31 | ||
| 2024-12-31 | -1.31 | |
| 2024-09-30 | -2.41 | -2.41 |
| 2024-06-30 | -2.73 | -2.73 |
| 2024-03-31 | -6.09 | -6.09 |
| 2023-12-31 | -6.77 | |
| 2023-09-30 | -14.40 | -14.40 |
| 2023-06-30 | -3.24 | -3.24 |
| 2023-03-31 | -34.84 | -34.84 |
| 2022-12-31 | -161.55 | |
| 2022-09-30 | -11.67 | -11.67 |
| 2021-12-31 | -3.25 | |
| 2020-12-31 | -4.15 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for TriSalus Life Sciences, Inc. - Equity Warrant as of June 30, 2025 is -28.37 MM.
- The cash from investing activities for TriSalus Life Sciences, Inc. - Equity Warrant as of June 30, 2025 is -0.84 MM.
- The cash from financing activities for TriSalus Life Sciences, Inc. - Equity Warrant as of June 30, 2025 is 39.22 MM.
| Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
| 2025-06-30 | -28.37 | -0.84 | 39.22 |
| 2025-03-31 | -34.48 | -0.99 | 44.50 |
| 2024-12-31 | -40.84 | -0.34 | 37.94 |
| 2024-09-30 | -44.31 | -0.67 | 34.98 |
| 2024-06-30 | -55.13 | -1.61 | 69.42 |
| 2024-03-31 | -50.94 | -1.58 | 49.83 |
| 2023-12-31 | -50.58 | -1.59 | 54.63 |
| 2023-09-30 | -49.71 | -1.49 | 60.49 |
| 2023-06-30 | -33.37 | -1.47 | 24.23 |
| 2023-03-31 | -32.23 | -1.46 | 21.33 |
| 2022-12-31 | -32.31 | -1.79 | 13.46 |
| 2022-09-30 | -28.49 | -2.06 | 11.66 |
| 2021-12-31 | -22.70 | -2.26 | 50.77 |
| 2020-12-31 | -15.58 | -9.70 | 24.81 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
| Period End (TTM) | p/e | P/Book | P/TBV |
| 2025-06-30 | |||
| 2025-03-31 | |||
| 2024-12-31 | |||
| 2024-09-30 | |||
| 2024-06-30 | |||
| 2024-03-31 | |||
| 2023-12-31 | |||
| 2023-09-30 | |||
| 2023-06-30 | |||
| 2023-03-31 | |||
| 2022-12-31 | |||
| 2022-09-30 | |||
| 2021-12-31 | |||
| 2020-12-31 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
| Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
| 2025-06-30 | ||
| 2025-03-31 | ||
| 2024-12-31 | ||
| 2024-09-30 | ||
| 2024-06-30 | ||
| 2024-03-31 | ||
| 2023-12-31 | ||
| 2023-09-30 | ||
| 2023-06-30 | ||
| 2023-03-31 | ||
| 2022-12-31 | ||
| 2022-09-30 | ||
| 2021-12-31 | ||
| 2020-12-31 |
Management Effectiveness
- The roa for TriSalus Life Sciences, Inc. - Equity Warrant as of June 30, 2025 is -0.84.
| Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
| 2025-06-30 | -0.84 | ||||
| 2025-03-31 | -1.52 | ||||
| 2024-12-31 | -1.17 | ||||
| 2024-09-30 | -1.65 | -6.51 | -18.32 | -3.31 | -14.52 |
| 2024-06-30 | -3.22 | ||||
| 2024-03-31 | -2.68 | ||||
| 2023-12-31 | -1.95 | -4.57 | -4.52 | 0.91 | -4.86 |
| 2023-09-30 | -1.71 | ||||
| 2023-06-30 | -1.40 | -1.71 | |||
| 2023-03-31 | -1.26 | -1.54 | |||
| 2022-12-31 | -2.66 | -1.59 | -2.40 | ||
| 2022-09-30 | -2.66 | -1.59 | -2.40 | ||
| 2021-12-31 | -3.55 | -0.93 | 0.84 | -0.73 | |
| 2020-12-31 |
Gross Margins
- The gross margin for TriSalus Life Sciences, Inc. - Equity Warrant as of June 30, 2025 is 0.86.
- The net margin for TriSalus Life Sciences, Inc. - Equity Warrant as of June 30, 2025 is -0.85.
- The operating margin for TriSalus Life Sciences, Inc. - Equity Warrant as of June 30, 2025 is -0.99.
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
| Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
| 2025-06-30 | 0.86 | -0.85 | -0.99 |
| 2025-03-31 | 0.86 | -0.85 | -0.99 |
| 2024-12-31 | 0.86 | -1.02 | -1.23 |
| 2024-09-30 | 0.87 | -2.05 | -1.52 |
| 2024-06-30 | 0.87 | -2.91 | -2.53 |
| 2024-03-31 | 0.86 | -3.19 | -2.93 |
| 2023-12-31 | 0.82 | -2.88 | -2.96 |
| 2023-09-30 | 0.80 | -3.59 | -2.81 |
| 2023-06-30 | 0.80 | -3.59 | -2.81 |
| 2023-03-31 | 0.80 | -3.66 | -2.97 |
| 2022-12-31 | 0.87 | -2.69 | -2.64 |
| 2022-09-30 | 0.87 | -2.69 | -2.64 |
| 2021-12-31 | 0.86 | -3.43 | -2.86 |
| 2020-12-31 | 0.60 | -5.86 | -4.72 |
Identifiers and Descriptors
| Central Index Key (CIK) | 1826667 |
Industry Groups
| SIC 3841 - Surgical and Medical Instruments and Apparatus |
